JNJ.N
現在値
150.13USD変化
0.04(+0.03%)出来高
2,181,566本日のレンジ
-
150.4852週レンジ
-
154.25∙ 約20分前の相場を表示しています。
Feb 13 (Reuters) - Johnson & Johnson <JNJ.N>::J&J - ON FEB 11, BOARD VOTED TO SUBMIT PROPOSAL AT ANNUAL MEETING RECOMMENDING APPROVAL OF AMENDMENT TO CO'S RESTATED CERTIFICATE OF INCORPORATION.J&J - PROPOSAL RECOMMENDS APPROVAL TO DELETE PROVISION PROVIDING THAT NO DIRECTOR MAY BE REMOVED BY VOTE OF SHAREHOLDERS, EXCEPT FOR CAUSE.J&J - PROPOSED AMENDMENT WILL BE SET FORTH IN DETAIL IN CO'S 2020 PROXY STATEMENT, WHICH WILL BE FILED IN ADVANCE OF 2020 ANNUAL MEETING.J&J - IN EVENT PROPOSED AMENDMENT IS APPROVED & BECOMES EFFECTIVE, BOARD WILL APPROVE A CONFORMING AMENDMENT TO CO'S BY-LAWS.
Feb 11 (Reuters) - Johnson & Johnson <JNJ.N>::JOHNSON & JOHNSON ANNOUNCES COLLABORATION WITH U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES TO ACCELERATE DEVELOPMENT OF A POTENTIAL NOVEL CORONAVIRUS VACCINE.J&J - "WORKING CLOSELY WITH GLOBAL PARTNERS TO SCREEN ITS LIBRARY OF ANTIVIRAL MOLECULES TO ACCELERATE DISCOVERY OF POTENTIAL COVID-19 TREATMENTS".J&J - JANSSEN AND BARDA WILL BOTH CONTRIBUTE TO RESEARCH AND DEVELOPMENT COSTS TO ADVANCE INITIAL STAGES OF COVID-19 VACCINE DEVELOPMENT PROGRAM.J&J - BARDA WILL PROVIDE FUNDING TO SUPPORT ACCELERATED DEVELOPMENT OF A VACCINE CANDIDATE INTO PHASE 1 CLINICAL STUDIES.J&J - AGREEMENT ALSO HAS OPTIONS FOR ADDITIONAL FUNDING FROM BARDA TO PROGRESS A PROMISING CANDIDATE.
Feb 10 (Reuters) - Johnson & Johnson <JNJ.N>::JANSSEN ANNOUNCES SUBMISSION TO U.S. FDA FOR NEW DARZALEX® (DARATUMUMAB)-BASED COMBINATION REGIMEN FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA.JANSSEN ONCOLOGY - SUBMISSION OF SUPPLEMENTAL BLA TO FDA SEEKING APPROVAL OF DARZALEX IN COMBINATION WITH KYPROLIS & DEXAMETHASONE.
Jan 29 (Reuters) - Janssen: :JANSSEN ANNOUNCES EUROPEAN COMMISSION APPROVAL FOR EXPANDED USE OF ERLEADA FOR TREATMENT OF PATIENTS WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER.EC APPROVAL BASED ON DATA FROM PHASE 3 TITAN STUDY, WHICH ASSESSED ADDITION OF APALUTAMIDE TO ADT IN A BROAD RANGE OF PATIENTS WITH MHSPC.APALUTAMIDE PLUS ADT SIGNIFICANTLY IMPROVED OS COMPARED TO PLACEBO PLUS ADT WITH A 33 PERCENT REDUCTION IN THE RISK OF DEATH.
Jan 27 (Reuters) - Janssen Pharmaceutical::JANSSEN - HEALTH CANADA HAS APPROVED STELARA FOR TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS.
Jan 23 (Reuters) - JANSSEN::JANSSEN - EUROPEAN COMMISSION APPROVES EXPANDED USE OF STELARA FOR TREATMENT OF PAEDIATRIC PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS.
Jan 22 (Reuters) - Johnson & Johnson <JNJ.N>::EXEC SAYS OVER 3,500 PATIENTS HAVE BEEN TREATED TO DATE WITH SPRAVATO AND PATIENT DEMAND CONTINUES TO BUILD - CONF CALL.CEO SAYS CO IS OPTIMIZING RESOURCES TO SAVE WATER AND ELECTRICITY AND EXPECTS TO REDUCE CARBON EMISSIONS BY 20% IN 2020 - CONF CALL.EXEC SAYS EXPECTS FREE CASH FLOW TO DECLINE IN 2020 DUE TO PAYMENT OF PREVIOUSLY DISCLOSED OPIOID LITIGATION - CONF CALL.EXEC SAYS 2020 FORECAST DOES NOT ASSUME ANY MAJOR ACQUISITIONS OR OTHER MAJOR USES OF CASH - CONF CALL.SAYS OFF-PATENT DRUGS WERE ABLE TO RETAIN BUSINESS A LITTLE LONGER THAN EXPECTED IN 2019, AND EXPECTS IT TO CONTINUE IN 2020 - CONF CALL.SAYS REMAINS "CAUTIOUSLY OPTIMISTIC" REGARDING OPIOID SETTLEMNT AND EXPECTS TO HEAR MORE UPDATES IN COMING MONTHS - CONF CALL.SAYS INDEPENDENT RESEARCH CONTINUES TO FIND NO LINK BETWEEN TALC AND CANCER - CONF CALL.SAYS CONTINUES TO WORK WITH NEGOTIATING COMMITTEE OF STATE ATTORNEYS GENERAL TO FINALIZE OPIOID SETTLEMENT AGREEMENT- CONF CALL.SAYS CO WILL NOT BE ACTIVE PARTICIPANT AT FDA EXPERT PANEL MEETING NEXT MONTH FOR DISCUSSING TESTING METHODS FOR DETECTING ASBESTOS IN TALC - CONF CALL.SAYS CO'S CURRENT INTERNAL TESTING METHODS FOR DETECTING ASBESTOS EXCEED THAT OF CURRENT FDA STANDARDS FOR COSMETIC TALC - CONF CALL.
Jan 22 (Reuters) - Johnson & Johnson <JNJ.N>::REPORTS 2019 FOURTH-QUARTER AND FULL YEAR RESULTS:.Q4 SALES $20.7 BILLION VERSUS REFINITIV IBES ESTIMATE OF $20.8 BILLION.Q4 ADJUSTED EARNINGS PER SHARE $1.88.Q4 EARNINGS PER SHARE $1.50.Q4 EARNINGS PER SHARE ESTIMATE $1.87 -- REFINITIV IBES DATA.J&J - COMPANY PROJECTS CONTINUED SALES AND EARNINGS GROWTH IN 2020 GUIDANCE.J&J - QTRLY WORLDWIDE REMICADE SALES $1.04 BILLION VERSUS $1.24 BILLION REPORTED LAST YEAR.J&J SEES 2020 OPERATIONAL SALES $85.8 TO $86.6 BILLION.J&J QTRLY WORLDWIDE IMBRUVICA SALES $875 MILLION VERSUS $703 MILLION.J&J SEES 2020 ESTIMATED REPORTED SALES $85.4 TO $86.2 BILLION.J&J SEES 2020 ADJUSTED OPERATIONAL SALES UP 5.0% - 6.0%.J&J QTRLY GAAP LITIGATION EXPENSE, NET $264 MILLION VERSUS $1.29 BILLION.J&J QTRLY WORLDWIDE ZYTIGA SALES $677 MILLION VERSUS $786 MILLION.FY2020 REVENUE VIEW $85.48 BILLION -- REFINITIV IBES DATA.J&J QTRLY WORLDWIDE DARZALEX SALES $830 MILLION VERSUS $584 MILLION.J&J SEES FY2020 ADJUSTED OPERATIONAL EPS (DILUTED) $9.00 TO $9.15.J&J SEES FY2020 ADJUSTED EPS (DILUTED) $8.95 TO $9.10.FY2020 EARNINGS PER SHARE VIEW $9.10 -- REFINITIV IBES DATA.
Jan 17 (Reuters) - :U.S. COURT KNOCKS DOWN RISPERDAL VERDICT AGAINST JOHNSON & JOHNSON'S JANSSEN UNIT TO $6.8 MILLION FROM $8 BILLION - LAW.COM.
Jan 15 (Reuters) - Janssen Pharmaceutical Companies of Johnson & Johnson::JANSSEN SEEKS EXPANDED USE OF SPRAVATO®▼ (ESKETAMINE) NASAL SPRAY IN EUROPE AS A TREATMENT FOR DEPRESSIVE SYMPTOMS IN ADULTS WITH MAJOR DEPRESSIVE DISORDER WHO HAVE CURRENT SUICIDAL IDEATION WITH INTENT.JANSSEN - SUBMISSION OF TYPE II VARIATION APPLICATION IS BASED ON RESULTS FROM 2 PHASE 3 CLINICAL STUDIES.JANSSEN - ANNOUNCED SUBMISSION OF A TYPE II VARIATION APPLICATION TO EUROPEAN MEDICINES AGENCY FOR SPRAVATO (ESKETAMINE) NASAL SPRAY.
金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。